Avastin is non-toxic

Article

Avastin (bevacizumab) does not exert any toxic effects on the retina and its function, according to a study published in the January issue of Retina journal.

Avastin (bevacizumab) does not exert any toxic effects on the retina and its function, according to a study published in the January issue of Retina journal.

A team led by Professor Peter Heidushka of the University Eye Hospital Tuebingen, Tuebingen, Germany, examined the retinal function of wild-type mice that received an intravitreal injection of Avastin.

Electroretinography (ERG) was performed on four different groups of mice: group 1) mice were injected intravitreally with BSS; group 2) mice received injections of a vehicle solution; group 3) mice were injected with Avastin solution; group 4) mice received sham surgery. ERG was performed before treatment and one, four, 12, and 25 days post treatment.

ERG parameters were similar in all four groups; no difference could be seen between eyes injected with Avastin and those receiving the vehicle solution. Bevacizumab immunoreactivity was present in the retina 30 mins after Avastin injection, but this was no longer detectable 25 days later.

The authors therefore concluded that Avastin does not have any harmful effects on the retina or its function; it penetrates the retina quickly and safely after injection.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.